7. Acute Myeloid Leukemia

  1. Hussain I. Saba MD, PHD2 and
  2. Ghulam J. Mufti MB, DM, FRCP, FRCPATH3
  1. Martin S. Tallman,
  2. Ritesh Parajuli and
  3. Jessica K. Altman

Published Online: 24 MAR 2011

DOI: 10.1002/9781444394016.ch7

Advances in Malignant Hematology

Advances in Malignant Hematology

How to Cite

Tallman, M. S., Parajuli, R. and Altman, J. K. (2011) Acute Myeloid Leukemia, in Advances in Malignant Hematology (eds H. I. Saba and G. J. Mufti), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444394016.ch7

Editor Information

  1. 2

    James A. Haley Veterans' Hospital, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, FL, USA

  2. 3

    Department of Haematological Medicine, Guy's and St Thomas' School of Medicine, King's College Hospital, London, UK

Author Information

  1. Northwestern University Feinberg School of Medicine, and Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, USA

Publication History

  1. Published Online: 24 MAR 2011
  2. Published Print: 16 APR 2011

ISBN Information

Print ISBN: 9781405196260

Online ISBN: 9781444394016

SEARCH

Keywords:

  • Acute Myeloid Leukemia

Summary

Acute myeloid leukemia (AML) is a heterogenous group of disorders that arise from the neoplastic transformation of a hematopoietic stem cell. Intensive investigations during the last two decades have provided insights into the pathogenesis of the disease and have revealed marked heterogeneity with respect to cytogenetics and molecular genetics of the malignant cells. The new World Health Organization (WHO) classification takes into account contemporary information about cytogenetic and molecular genetics and whether the disease arises from an antecedent hematological disorder or evolves as a result of prior chemotherapy exposure.

Despite current strategies, including intensive induction and consolidation chemotherapy, and improvements in allogeneic hematopoietic stem cell transplantation, many younger adults and almost all older adults with AML die of their disease. Recently, advances in immunophenotyping, karyotypic analysis, and molecular biology have led to important developments in tailored and targeted therapy. It is likely that, with further insights into the mechanisms of cell cycle control, apoptosis, differentiation, and cellular antigen expression, new targeted therapeutic strategies will be developed and perhaps even lead to the eradication of the leukemia stem cell.